Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management

Epidermal growth factor inhibitors (EGFRI), the first targeted cancer therapy, are currently an essential treatment for many advance-stage epithelial cancers. These agents have the superior ability to target cancers cells and better safety profile compared to conventional chemotherapies. However, cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chanprapaph, K., Vachiramon, V., Rattanakaemakorn, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958662/
https://www.ncbi.nlm.nih.gov/pubmed/24723942
http://dx.doi.org/10.1155/2014/734249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958662/
https://www.ncbi.nlm.nih.gov/pubmed/24723942
http://dx.doi.org/10.1155/2014/734249

Ejemplares similares